Effects of organic anion transporting polypeptide IBI haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril

Objective: Recent reports have shown that genetic polymorphisms in organic anion transporting polypeptide (OATP) 1B1 have an effect on the pharmacokinetics of drugs. However, the impact of OATP1B1*1b alleles, the frequency of which is high in all ethnicities, on the pharmacokinetics of substrate drugs is not known after complete separation of subjects with OATP1B1*1a and *1b. Furthermore, the correlation between the clearances of OATP1B1 substrate drugs in individuals has not been characterized. We investigated the effect of genetic polymorphism of OATP1B1, particularly the *1b allele, on the pharmacokinetics of 3 anionic drugs, pravastatin, valsartan, and temocapril, in Japanese subjects. Methods: Twenty-three healthy Japanese volunteers were enrolled in a 3-period crossover study. In each period, after a single oral administration of pravastatin, valsartan, or temocapril, plasma and urine were collected for up to 24 hours. Results: The area under the plasma concentration-time curve (AUC) of pravastatin in *1b/*1b carriers (47.4 +/- 19.9 ng (.) h/mL) was 65% of that in *1a/*1a carriers (73.2 +/- 23.5 ng (.) h/mL) (P =.049). Carriers of 15 (38.2 +/- 15.9 ng (.) h/mL) exhibited a 45% lower AUC than *1a/*15 carriers (69.2 +/- 23.4 ng (.) h/mL) (P =.024). In the case of valsartan we observed a similar trend as with pravastatin, although the difference was not statistically significant (9.01 +/- 3.33 mu g (.) h/mL for *1b/*1b carriers versus 12.3 +/- 4.6 mu g (.) h/mL for *1a/*1a carriers [P =.171] and 6.31 +/- 3.64 mu g (.) h/mL for *1b/*15 carriers versus 9.40 +/- 4.34 mu g (.) h/mL for *1a/*15 carriers [P =.213]). The AUC of temocapril also showed a similar trend (12.4 +/- 4.1 ng (.) h/mL for *1b/*1b carriers versus 18.5 +/- 7.7 ng (.) h/mL for *1a/*1a carriers [P =.061] mid 16.4 +/- 5.0 ng (.) h/mL for *1b/*15 carriers versus 19.0 +/- 4.1 ng (.) h/mL for *1a/*15 carriers [P =.425]), whereas that of temocaprilat (active form of temocapril) was not significantly affected by the haplotype of OATP1B1. Interestingly, the AUC of valsartan and temocapril in each subject was significantly correlated with that of pravastatin (R = 0.630 and 0.602, P <.01). The renal clearance remained unchanged for each haplotype for all drugs. Conclusion: The major clearance mechanism of pravastatin, valsartan, and temocapril appears to be similar, and OATP1B1*1b is one of the determinant factors governing the interindividual variability in the pharmacokinetics of pravastatin and, possibly, valsartan and temocapril.